Form D · Biotechnology
Marval Biosciences Inc
San Diego, CA · CIK 0001412586
Offering snapshot reported Jul 26, 2012 · SEC filing
- Reported sold
- $2.5M Offering amount: $30M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Jul 24, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 26, 2012 | Initial | $2,500,000 | No comparison | 12 | SEC filing |
| Nov 2, 2011 | Initial | $1,516,515 | No comparison | 11 | SEC filing |
| Sep 28, 2009 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Sep 13, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-181837
Source: Form D, filed Jul 26, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ananth Annapragada | Director, Executive |
| Frank Foster | Director |
| Russell Lebovitz | Director, Executive |
| Dan Watkins | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1441 9 Th Unit 2001
San Diego, CA, 92101-8947
San Diego, CA, 92101-8947